The NCCN Annual Conference: Advancing the Standard of Cancer Care™ attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and supportive care areas. The NCCN Annual Conference also includes case study discussion forums with experts from NCCN Member Institutions and roundtable discussions featuring the foremost professionals from the academic, patient advocacy, government, payer, industry, and business realms of cancer care.
- Case Manager: 15.00
- Health Care Other: 15.00
- Nurse: 15.96
- Pharmacist: 15.00
- Physician: 15.00
- Tumor Registrar: 15.00
- Event starts: Thu, Mar 13 2014 - 8:00 am
- Event ends: Sat, Mar 15 2014 - 8:00 pm
- Course opens: Thu, Mar 13 2014
- Course expires: Sun, Aug 31 2014
This conference is designed to meet the educational needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this program, participants should be able to:
- Integrate into professional practice the key updates of the NCCN Guidelines related to basal and squamous cell skin cancers, breast cancer, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), colorectal cancer, gallbladder cancer, melanoma, multiple myeloma, non-small cell lung cancer (NSCLC), Non-Hodgkin’s lymphomas (NHL), prostate cancer, and cancer survivorship.
- Integrate into professional practice the treatment and survivorship recommendations for the management of chemotherapy-induced peripheral neuropathy and cognitive decline.
- Integrate into professional practice treatment strategies for use of myeloid and erythropoietic growth factors, management of dermatologic toxicities resulting from targeted agents, communicating with patients about optimal post-treatment surveillance, consideration of cultural diversity in delivering and receiving oncology care and maintaining bone health.
Required hardware / software
Supported by an educational donation provided by Amgen. Supported by educational grants from AbbVie Inc.; Bayer, along with Algeta US; Bristol-Myers Squibb; CELGENE CORPORATION; Eisai Inc; Genentech; Gilead Sciences, Inc.; Janssen Biotech, Inc., administered by Janssen Services, LLC; Lilly; Merck Sharp & Dohme Corp.; Millennium: The Takeda Oncology Company; Novartis Oncology; Onyx Pharmaceuticals; Pfizer; Pinnacle Biologics, Inc.; Spectrum Pharmaceuticals, Inc.; and Teva Pharmaceuticals.